SunAct Cancer Institute ties up with Singapore’s CytoMed for phase 2 clinical trials on innovative cancer therapy in India

This is a cutting-edge cancer treatment that uses special immune cells called Gamma Delta T-Cells

0
57
New Delhi: SunAct Cancer Institute has announced the start of Phase 2 clinical trials on a groundbreaking treatment called gd (Gamma Delta) T-cell therapy. This trial, conducted in collaboration with CytoMed, Singapore, aims to bring hope to patients with difficult-to-treat cancers such as brain cancer, breast cancer, lung cancer, cervical cancer, colon cancer, renal cancer, liver cancer, lymph node cancer and several others.
The gd (Gamma Delta) T-Cell Therapy is a cutting-edge cancer treatment that uses special immune cells called Gamma Delta T-Cells. These cells naturally fight cancer while protecting the healthy tissue. What makes this treatment unique is that it uses ready-made cells from donors, making it faster, easier, and less expensive compared to traditional therapies.
“Our goal is to provide advanced and affordable cancer treatments to patients in India,” said Dr. (Prof) Vijay Patil, Founder of SunAct Cancer Institute. “Gamma Delta T-Cell therapy is a promising solution for solid tumors, and through this collaboration with CytoMed, we hope to improve the lives of many cancer patients,” he added.
CytoMed’s Chairman Peter Choo said, “CytoMed’s collaboration with SunAct is timely and complements our core focus of harnessing CytoMed’s proprietary off-the-shelf technologies to develop novel donor-derived cell-based allogenic immunotherapies for the treatment of various cancers at affordable cost. We are aligned with the foresight of our partner SunAct to provide affordable no-option cancer therapeutics and are excited to work with Dr. Vijay Patil in our strive to accelerate the therapeutic application of CytoMed’s patented allogenic gamma delta T-Cells in, an increasing population of cancer patients in India and around the world.”